- Oncternal Therapeutics Inc (NASDAQ:ONCT) will suspend Phase 3 and the Phase 1/2 studies of zilovertamab in combination with ibrutinib, citing the rapidly changing commercial landscape for Bruton’s tyrosine kinase inhibitors (BTK inhibitors).
- Cash, cash equivalents, and short-term investments of $54.3 million as of March 31, 2023, will support planned operations into 2025, supporting two pipeline assets, ONCT-808 and ONCT-534.
- ONCT-808: ROR1 targeting autologous CAR T cell therapy is being tested in a recently initiated Phase 1/2 clinical trial for relapsed or refractory aggressive B-cell lymphoma.
- Preclinical models show robust and specific activity against ROR1-expressing cells from multiple tumor types.
- The manufacturing process is reproducible, scalable, and only eight days in duration.
- The company expects to present initial clinical data in late 2023, with additional clinical data readouts in 2024.
- ONCT-534: Dual-action androgen receptor inhibitor (DAARI) has concluded IND-enabling studies and an Investigational New Drug Application (IND) is expected to be submitted in mid-2023.
- Initial clinical data is expected to be presented in mid-2024.
- Price Action: ONCT shares are down 58.20% at $0.33 on the last check Tuesday.
Reported Late Friday, OpGen Announces Pricing Of $7.5M Public Offering Of 2,586,207 Shares Of Common Stock At A Price Of $2.90/Share
OpGen, Inc. (NASDAQ:OPGN, ", OpGen", or ", the Company", )))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today
